Cordlife GroupCLIFF 41 Net Debt Paydown Yield % is 1.17% as of Jul. 05, 2026, which is 50% below its 10-year median of 2.35. GuruFocus rates CLIFF with a GF Score™ of 41/100 and a GF Value™ of $0.17 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 199 Medical Diagnostics & Research companies, Cordlife Group ranks better than 75.88% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Cordlife Group's Net Debt Paydown Yield % was 1.17%.
Cordlife Group (OTCPK:CLIFF) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Cordlife Group Net Debt Paydown Yield % Related Terms
Cordlife Group Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Cordlife Group's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLIFF vs TMO, DHR, IDXX: Net Debt Paydown Yield % Comparison
For the Diagnostics & Research subindustry, Cordlife Group's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cordlife Group Net Debt Paydown Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cordlife Group's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Cordlife Group's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 1.17% mean?
Cordlife Group (CLIFF) has a Net Debt Paydown Yield % of 1.17% as of Jul. 05, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Cordlife Group and its competitors. This is 50% below median its historical median of 2.35. According to the industry distribution chart, Cordlife Group ranks #48 out of 199 companies in the Medical Diagnostics & Research industry, placing it in the top 24.1%.
Is Cordlife Group's Net Debt Paydown Yield % too high?
Cordlife Group's current Net Debt Paydown Yield % of 1.17% is 50% below median its 10-year median of 2.35. Based on the distribution chart, Cordlife Group ranks #48 out of 199 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cordlife Group has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cordlife Group's Net Debt Paydown Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cordlife Group ranks #48 out of 199 companies for Net Debt Paydown Yield %. This places Cordlife Group in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Diagnostics & Research company?
A good Net Debt Paydown Yield % depends on the Medical Diagnostics & Research industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Cordlife Group and its competitors. Cordlife Group's current Net Debt Paydown Yield % is 1.17%, which is 50% below median its own 10-year median of 2.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cordlife Group stock overvalued right now?
Based on GuruFocus' analysis, Cordlife Group (CLIFF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.17, compared to a current price of $0.15 — trading 11.5% below its estimated fair value. The current Net Debt Paydown Yield % is 1.17%, which is 50% below median its 10-year median of 2.35. Cordlife Group's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Cordlife Group (CLIFF), the current Net Debt Paydown Yield % is 1.17% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cordlife Group (CLIFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cordlife Group stock appears to be undervalued.
The current stock price of $0.15 is trading 11.5% below its estimated GF Value™ of $0.17.
GuruFocus considers Cordlife Group to be Significantly Overvalued.
Key valuation signals for CLIFF:
Net Debt Paydown Yield %: 1.17% (50% below median its 10-year median of 2.35)
GF Value™: $0.17 vs. price of $0.15 (11.5% below fair value)
No single metric tells the full story. See the CLIFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cordlife Group Ltd is a consumer healthcare company dedicated to safeguarding the well-being of mother and child. Along with its subsidiaries, the company is engaged in the provision of diagnostics and cord blood banking services, which involve the processing and storage of cord blood stem cells. The group has two reportable segments as follows: the Banking segment, which derives maximum revenue, comprises the collection, processing, and banking of biological materials; and the Diagnostics segment, which comprises diagnostics testing services. Geographically, the group generates maximum revenue from Hong Kong, and the rest from the Philippines, India, Malaysia, Singapore, and other regions.
41GF Score
Get the complete analysis for CLIFF
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLIFF has been successfully added to your 
